Barriers to initiating treatment may include delayed recognition of obesity as a disease by public health and medical organizations, provider biases regarding patients with obesity, lack of reimbursement leading to out-of-pocket costs to patients, inadequate training of providers, historical safety issues with AOMs, and perceptions of patients and their caregivers regarding the efficacy of AOMs [14,15,16,17]
The Faseb Journal , 26 (10), 40454056
Starting a GLP-1
Available from: www.anvpublication.orgwww.asianpharmaonline.orgHomepagewww.ajpaonline.com Akowuah GA, Htar TT
A: The exact dosage is determined by a physician, tailored to individual health needs and medical condition, and should not be self-administered without medical advice.
2020;232 doi: 10.1016/j.biomaterials.2019.119736